Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Koninklijke Philips NVRYLPF 66 Future 3-5Y EPS without NRI Growth Rate is 10.67 as of Aug. 31, 2026. GuruFocus rates RYLPF with a GF Score™ of 66/100 and a GF Value™ of $25.07 (Fairly Valued). The stock has 2 warning signs investors should review. Among 282 Medical Devices & Instruments companies, Koninklijke Philips NV ranks worse than 77.66% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Koninklijke Philips NV Future 3-5Y EPS without NRI Growth Rate Related Terms
RYLPF vs ABT, SYK, MDT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Koninklijke Philips NV's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Koninklijke Philips NV Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Koninklijke Philips NV's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Koninklijke Philips NV's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 10.67 mean?
Koninklijke Philips NV (RYLPF) has a Future 3-5Y EPS without NRI Growth Rate of 10.67 as of Aug. 31, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Koninklijke Philips NV and its competitors. According to the industry distribution chart, Koninklijke Philips NV ranks #219 out of 282 companies in the Medical Devices & Instruments industry, placing it in the top 77.7%.
Is Koninklijke Philips NV's Future 3-5Y EPS without NRI Growth Rate too high?
Koninklijke Philips NV's current Future 3-5Y EPS without NRI Growth Rate is 10.67. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.78. Koninklijke Philips NV's value of 10.67 is 48.6% below this industry median. Based on the distribution chart, Koninklijke Philips NV ranks #219 out of 282 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Koninklijke Philips NV has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's Future 3-5Y EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Koninklijke Philips NV ranks #219 out of 282 companies for Future 3-5Y EPS without NRI Growth Rate. This places Koninklijke Philips NV in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.78. Koninklijke Philips NV's value of 10.67 is 48.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.78, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Koninklijke Philips NV's current Future 3-5Y EPS without NRI Growth Rate of 10.67 is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Koninklijke Philips NV and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Koninklijke Philips NV's current Future 3-5Y EPS without NRI Growth Rate is 10.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $25.07, compared to a current price of $27.58 — trading 10% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 10.67 and 48.6% below the Medical Devices & Instruments industry median of 20.78. Koninklijke Philips NV's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current Future 3-5Y EPS without NRI Growth Rate is 10.67 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued.
The current stock price of $27.58 is trading 10% above its estimated GF Value™ of $25.07.
GuruFocus considers Koninklijke Philips NV to be Fairly Valued.
Key valuation signals for RYLPF:
Future 3-5Y EPS without NRI Growth Rate: 10.67
GF Value™: $25.07 vs. price of $27.58 (10% above fair value)
Industry Position: 48.6% below the Medical Devices & Instruments median (#219 of 282)
No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
66GF Score
Get the complete analysis for RYLPF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYLPF has been successfully added to your 
